Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality

摘要

Treating coronavirus disease 2019 (COVID-19) using ACE(angiotensin-converting enzyme) inhibitors and angio-tensin II receptor blockers (ARBs) is a clinical dilemma dueto the perceived risk of exacerbating COVID-19 by elevatingACE2 expression. 1 Despite recent studies showing no harm tocontinue ACE inhibitors/ARBs in the setting of COVID-19, 2,3it is still unknown whether ACE inhibitors and ARBs haveequivalent impacts on COVID-19 mortality among patientspreexisting different indications.